This was complemented by a prognostic analysis using the LinkedOmics and GEPIA databases, which presented a positive correlation between higher SOX3 levels and improved overall survival rates in GBM patients, suggesting SOX3 potential as a prognostic biomarker [69]. The gene discussed is SOX3; the disease is glioblastoma.